Search results for " ADR"

showing 10 items of 285 documents

Role of α1-adrenoceptor subtypes on corneal epithelial thickness and cell proliferation in mice

2018

Adrenergic stimuli are important for corneal epithelial structure and healing. The purpose of the present study was to examine the hypothesis that the lack of a single α1-adrenoceptor (α1-AR) subtype affects corneal epithelial thickness and cell proliferation. Expression levels of α1-AR mRNA were determined in mouse cornea using real-time PCR. In mice devoid of one of the three α1-AR subtypes (α1A-AR−/−, α1B-AR−/−, α1D-AR−/−) and in wild-type controls, thickness of individual corneal layers, the number of epithelial cell layers, and average epithelial cell size were determined in cryosections. Endothelial cell density and morphology were calculated in corneal explants, and epithelial cell p…

0301 basic medicinePhysiologyChemistryCell growthAdrenergicCell Biologyα1 adrenoceptorCell biology03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structure030221 ophthalmology & optometrymedicineα adrenoceptorsCorneal epitheliumAmerican Journal of Physiology-Cell Physiology
researchProduct

Iron-loaded transferrin (Tf) is detrimental whereas iron-free Tf confers protection against brain ischemia by modifying blood Tf saturation and subse…

2018

Despite transferrin being the main circulating carrier of iron in body fluids, and iron overload conditions being known to worsen stroke outcome through reactive oxygen species (ROS)-induced damage, the contribution of blood transferrin saturation (TSAT) to stroke brain damage is unknown. The objective of this study was to obtain evidence on whether TSAT determines the impact of experimental ischemic stroke on brain damage and whether iron-free transferrin (apotransferrin, ATf)-induced reduction of TSAT is neuroprotective. We found that experimental ischemic stroke promoted an early extravasation of circulating iron-loaded transferrin (holotransferrin, HTf) to the ischemic brain parenchyma.…

0301 basic medicineU-PAGE urea-polyacrylamide gel electrophoresisMaleClinical BiochemistryExperimental strokeBiochemistryBrain IschemiaBrain ischemia0302 clinical medicineADC apparent diffusion coefficientApotransferrinDWI diffusion-weighted imagingTANDEM-1 Thrombolysis and Deferoxamine in Middle Cerebral Artery Occlusion clinical trialrHTf rat HTfrATf rat ATflcsh:QH301-705.5chemistry.chemical_classificationNeuronslcsh:R5-920ChemistryTransferrinExtravasationNS21 a medium supplement to grow neuronspDAPK-1 phosphorylated anti-death-associated protein kinase 1NeuroprotectionStrokeWB Western blotFemalemedicine.symptomlcsh:Medicine (General)Research PaperhHTf human HTfPC12 cell line derived from a pheochromocytoma of the rat adrenal medullamedicine.medical_specialtyIron OverloadBBB blood-brain barrierNMDAR N-methyl-D-aspartate receptorDCF dihydrofluoresceinIronWGA wheat germ agglutininHTf holotransferrinTransferrin receptorBrain damageTfR transferrin receptorDeferoxamineNeuroprotectionPI propidium iodide03 medical and health sciencesBrain damageCM conditioned mediumROS reactive oxygen speciesInternal medicine4-HNE 4-hydroxynonenalTf transferrinReceptors TransferrinmedicineFeRhoNoxTM-1 probe to detect Fe2+AnimalsHumansATf apotransferrinCM-H2DCFDA 5-chloromethyl-27-dichlorodihydrofluorescein diacetateMCAO middle cerebral artery occlusionDMT-1 divalent metal transporterB-27 a medium supplement to grow neuronsReactive oxygen speciesNMDA N-methyl-D-aspartateTSAT blood transferrin saturationTransferrin saturationBlood transferrin saturation (TSAT)Organic ChemistryNIR near infraredReactive oxygen species (ROS)medicine.diseasepMCAO permanent middle cerebral artery occlusionRatsPWI perfusion-weighted imaging030104 developmental biologyEndocrinologylcsh:Biology (General)TransferrinDAPK-1 anti-death-associated protein kinaseOGD oxygen/glucose deprivationTTC 235-triphenyl-tetrazolium chlorideLipid PeroxidationMCA middle cerebral arteryApoproteinsReactive Oxygen SpeciesMRI magnetic resonance imagingtMCAO transient middle cerebral artery occlusion030217 neurology & neurosurgeryhATf human ATf
researchProduct

Glycometabolic Alterations in Secondary Adrenal Insufficiency: Does Replacement Therapy Play a Role?

2018

Secondary adrenal insufficiency (SAI) is a potentially life-threatening endocrine disorder due to an impairment of corticotropin (ACTH) secretion from any process affecting the hypothalamus or pituitary gland. ACTH deficit can be isolated or associated with other pituitary failures (hypopituitarism). An increased mortality due to cardiovascular, metabolic, and infectious diseases has been described in both primary and secondary adrenal insufficiency. However, few studies have provided compelling evidences on the underlying mechanism in SAI, because of the heterogeneity of the condition. Recently, some studies suggested that inappropriate glucocorticoid (GCs) replacement therapy, as for dose…

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and MetabolismMini Reviewbody mass index; diabetes mellitus; glucocorticoids; impaired glucose tolerance; insulin resistance; metabolic syndrome; secondary adrenal insufficiency; weight gain030209 endocrinology & metabolismbody mass indexHypopituitarismlcsh:Diseases of the endocrine glands. Clinical endocrinologymetabolic syndromeGrowth hormone deficiencyImpaired glucose tolerance03 medical and health sciences0302 clinical medicineInsulin resistanceEndocrinologyInternal medicineDiabetes mellitusinsulin resistanceMedicineEndocrine systemlcsh:RC648-665glucocorticoidsbusiness.industryweight gainmedicine.disease030104 developmental biologyEndocrinologyimpaired glucose tolerancediabetes mellitussecondary adrenal insufficiencyMetabolic syndromebusinessGlucocorticoidmedicine.drug
researchProduct

Cardiac and vascular alpha(1)-adrenoceptors in congestive heart failure: a systematic review

2020

As heart failure (HF) is a devastating health problem worldwide, a better understanding and the development of more effective therapeutic approaches are required. HF is characterized by sympathetic system activation which stimulates α- and β-adrenoceptors (ARs). The exposure of the cardiovascular system to the increased locally released and circulating levels of catecholamines leads to a well-described downregulation and desensitization of β-ARs. However, information on the role of α-AR is limited. We have performed a systematic literature review examining the role of both cardiac and vascular α1-ARs in HF using 5 databases for our search. All three α1-AR subtypes (α1A, α1B and α1D) are exp…

0301 basic medicinemedicine.medical_specialtyα1-adrenoceptorsα(1)-adrenoceptorsmedicine.medical_treatmentheart failurecardiomyocyteReview030204 cardiovascular system & hematologyModels Biological03 medical and health sciences0302 clinical medicineDownregulation and upregulationblood vesselInternal medicineReceptors Adrenergic alpha-1medicineHumanslcsh:QH301-705.5Desensitization (medicine)business.industryMyocardiumα<sub>1</sub>-adrenoceptorsGeneral Medicinemedicine.diseaseα1 adrenoceptor030104 developmental biologySystematic reviewmedicine.anatomical_structurelcsh:Biology (General)Heart failureCardiologyBlood VesselsbusinessBlood vesselSignal Transduction
researchProduct

The Role of Adrenoceptors in the Retina

2020

The retina is a part of the central nervous system, a thin multilayer with neuronal lamination, responsible for detecting, preprocessing, and sending visual information to the brain. Many retinal diseases are characterized by hemodynamic perturbations and neurodegeneration leading to vision loss and reduced quality of life. Since catecholamines and respective bindings sites have been characterized in the retina, we systematically reviewed the literature with regard to retinal expression, distribution and function of alpha1 (α1)-, alpha2 (α2)-, and beta (β)-adrenoceptors (ARs). Moreover, we discuss the role of the individual adrenoceptors as targets for the treatment of retinal diseases.

0301 basic medicineretinaAdrenergic receptorgenetic structuresCentral nervous systemReviewα<sub>1</sub>-ARBiology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRetinal DiseasesmedicinedistributionAnimalsHumansα1-ARlcsh:QH301-705.5NeuronsRetinafunctionBinding Sitesα<sub>2</sub>-ARNeurodegenerationRetinalNeurodegenerative DiseasesGeneral Medicinemedicine.diseaseeye diseasesReceptors Adrenergic030104 developmental biologymedicine.anatomical_structurechemistrylcsh:Biology (General)β-ARNeuroscience030217 neurology & neurosurgeryα2-ARCells
researchProduct

Neuropeptide Y effects on pineal melatonin synthesis in the rat

1987

Neuropeptide Y (NPY)-like immunoreactivity is present in the rodent pineal gland. To elucidate possible effects on pineal melatonin synthesis NPY (5 nmol/kg body wt.) was injected into the common carotid artery of male rats. Activities of the melatonin biosynthetic enzymes, serotonin N-acetyltransferase (NAT) and hydroxyindole-O-methyltransferase (HIOMT) were determined by means of radioenzymatic methods. Intact light-exposed animal showed increased NAT activity at day- and at nighttime. Blinded animals showed a more than 10-fold reduction of NAT activity after nocturnal NPY injections. HIOMT activity was only slightly influenced at either time. These results are discussed in terms of the p…

Acetylserotonin O-MethyltransferaseMaleendocrine systemmedicine.medical_specialtyNeuroeffectorArylamine N-AcetyltransferaseBiologyPineal GlandMelatoninNorepinephrinePineal glandNorepinephrineInternal medicinemental disordersmedicineAnimalsNeuropeptide YMelatoninArylamine N-acetyltransferaseGeneral NeuroscienceRats Inbred StrainsNeuropeptide Y receptorhumanitiesRatsReceptors AdrenergicEndocrinologymedicine.anatomical_structureAcetylserotonin O-methyltransferaseSerotoninmedicine.drugNeuroscience Letters
researchProduct

Symptom variability and control in COPD: Advantages of dual bronchodilation therapy

2017

Abstract Background Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder characterized by usually progressive development of airflow obstruction that is not fully reversible. While most patients will experience symptoms throughout the day or in the morning upon awakening, many patients do not experience their symptoms as constant but report variability in symptoms during the course of the day or over time. Symptom variability adversely affects patients' health status and increases the risk of COPD exacerbations. Methods We examined data from the literature on symptom variability and control in patients with COPD, with focus on the use of inhaled bronchodilator therapy wi…

Aclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Pulmonary and Respiratory MedicineAclidiniumHealth StatusVital CapacityHealth StatuPulmonary Disease Chronic Obstructive0302 clinical medicineForced Expiratory VolumeFormoterol FumarateBronchodilatorBronchodilationFormoterol030212 general & internal medicineAclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Administration Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Disease Progression; Dose-Response Relationship Drug; Drug Therapy Combination; Forced Expiratory Volume; Formoterol Fumarate; Health Status; Humans; Muscarinic Antagonists; Pulmonary Disease Chronic Obstructive; Quality of Life; Treatment Outcome; Tropanes; Vital CapacityLung functionCOPDbiologyChronic obstructive pulmonary diseaseTropaneLamaBronchodilator AgentsMuscarinic AntagonistTreatment OutcomeInhalationAdministrationCombinationDisease ProgressionDrug Therapy CombinationDrugHumanmedicine.drugAdrenergic beta-2 Receptor AgonistPulmonary and Respiratory MedicineChronic Obstructivemedicine.medical_specialtymedicine.drug_classSymptom variabilitySocio-culturaleMuscarinic AntagonistsSettore MED/10 - Malattie Dell'Apparato RespiratorioDose-Response RelationshipPulmonary Disease03 medical and health sciencesDrug TherapyAdministration InhalationmedicineHumansIntensive care medicineAdrenergic beta-2 Receptor AgonistsBronchodilator AgentDose-Response Relationship Drugbusiness.industryMuscarinic antagonistDual bronchodilator therapymedicine.diseasebiology.organism_classificationLung functionrespiratory tract diseasesAclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Administration Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Disease Progression; Dose-Response Relationship Drug; Drug Therapy Combination; Forced Expiratory Volume; Formoterol Fumarate; Health Status; Humans; Muscarinic Antagonists; Pulmonary Disease Chronic Obstructive; Quality of Life; Treatment Outcome; Tropanes; Vital Capacity; Pulmonary and Respiratory MedicineDual bronchodilation030228 respiratory systemQuality of LifeFormoterolbusinessTropanesRespiratory Medicine
researchProduct

Role of Adrenomedullin in LSP-mediated lung injury

2014

Acute Respiratory Distress Syndrome adrenomedullin lipopolysaccharide Hsp32 MAPK p38MAPK
researchProduct

‘La chiamiamo con entrambi i nomi’: eponimia ed eteronimia tra Nemesis e Adrasteia

2020

Prendendo le mosse da un passo di Ammiano Marcellino (XIV 11,25), che lascia emergere un’evidente sovrapposizione tra la figura di Adrasteia e quella Nemesis, il contributo si propone di esaminare le ragioni che hanno condotto le due potenze ad essere indicate l’una come l’eteronimo dell’altra. A partire dalle fonti di V secolo fino alla paremiografia e alla lessicografia di età imperiale si ricostruisce un percorso che si propone di mostrare gli accidenti e le molteplici variabili cui le logiche di denominazione del divino, nel mondo greco, possono essere soggette. Starting from a passage by Ammiano Marcellino (XIV 11,25), which reveals an evident overlap between the figure of Adrasteia an…

AdrasteiaHistoryAdrastosNemesisCroesusHerodotusErodotoLexicographySettore L-ANT/02 - Storia GrecaAmmiano Marcellino Adrasteia Nemesis Herodotus Croesus Adrastos Greek ancient ReligionAdrastoAmmiano Marcellino Adrasteia Nemesis Erodoto Creso Adrasto Religione greca anticaPath (graph theory)General Earth and Planetary SciencesCresoHumanitiesGeneral Environmental Science
researchProduct

Trattamento laparoscopico del Mielolipoma surrenalico: caso clinico e revisione della letteratura.

2006

Adrenal myelolipoma is a rare benign, non-functioning tumor consisting of fat and hematopoietic tissues. In January 2005 we had observed an adrenal myelolipoma in 70 year old man. During the follow-up for bladder urothelioma, an abdominal CT revaled a well delineated 4x4 cm homogeneous fatty mass in the right suprarenal area with negative attenuation values. The functional study of adrenal gland was normal. The patient underwent videolaparoscopic right adrenalectomy (Gagner technique). Postoperative course was uneventful. The istological diagnosis showed adrenal myelolipoma. We conclude that videolaparoscopic adrenalectomy should be considered the gold standard treatment for benign adrenal …

Adrenal myelolipoma Gagner technique bladder urothelioma videolaparoscopic adrenalectomy
researchProduct